We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+34.79%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$152M
AUM Growth
+$22.9M
(+18%)
Cap. Flow
-$5.55M
Cap. Flow
% of AUM
-3.66%
Top 10 Holdings %
Top 10 Hldgs %
33.53%
Holding
141
New
14
Increased
30
Reduced
63
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Veritone
VERI
|
+$1.36M |
| 2 |
TEUM
Pareteum Corporation
TEUM
|
+$1.26M |
| 3 |
Natera
NTRA
|
+$1.12M |
| 4 |
CEMI
Chembio diagnostics, Inc.
CEMI
|
+$983K |
| 5 |
AbbVie
ABBV
|
+$879K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$2.81M |
| 2 |
CareDx
CDNA
|
+$1.92M |
| 3 |
Apyx Medical
APYX
|
+$1.7M |
| 4 |
Vericel Corp
VCEL
|
+$1.1M |
| 5 |
Intel
INTC
|
+$976K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.87% |
| 2 | Technology | 16.42% |
| 3 | Industrials | 5.82% |
| 4 | Communication Services | 5.78% |
| 5 | Consumer Discretionary | 2.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vericel Corp
VCEL
$2.1B
| $8.49M | 5.59% |
485,150
-59,900
| -11% | -$1.1M |
|
2
Axogen
AXGN
$2.77B
| $7.35M | 4.84% |
349,125
-7,050
| -2% | -$129K |
|
|
TEUM
3
DELISTED
Pareteum Corporation
TEUM
| $6.12M | 4.03% |
1,345,407
+376,428
| +39% | +$1.26M |
|
4
NeoGenomics
NEO
$2.32B
| $5.42M | 3.57% |
264,650
-16,850
| -6% | -$293K |
|
5
Veracyte
VCYT
$3.48B
| $4.94M | 3.25% |
197,440
-11,265
| -5% | -$215K |
|
6
Standard BioTools
LAB
$252M
| $4.4M | 2.9% |
331,150
+6,350
| +2% | +$66.9K |
|
|
7
CareDx
CDNA
$2.58B
| $4.16M | 2.74% |
131,900
-66,060
| -33% | -$1.92M |
|
8
Magnite
MGNI
$3.4B
| $3.83M | 2.52% |
630,350
-16,400
| -3% | -$84.4K |
|
|
9
Abbott
ABT
$195B
| $3.13M | 2.06% |
39,154
-37,746
| -49% | -$2.81M |
|
|
CSII
10
DELISTED
Cardiovascular Systems, Inc.
CSII
| $3.08M | 2.03% |
79,650
-4,500
| -5% | -$153K |
|
11
Idexx Laboratories
IDXX
$43.7B
| $2.98M | 1.97% |
13,350
| – | – |
|
12
OptimizeRx
OPRX
$150M
| $2.72M | 1.79% |
213,961
-935
| -0.4% | -$12.2K |
|
13
Sensus Healthcare
SRTS
$57.9M
| $2.69M | 1.77% |
383,036
-1,800
| -0.5% | -$13.9K |
|
14
Eli Lilly
LLY
$1.05T
| $2.69M | 1.77% |
20,710
-2,900
| -12% | -$353K |
|
|
15
Natera
NTRA
$47B
| $2.68M | 1.76% |
129,900
+71,200
| +121% | +$1.12M |
|
16
Rockwell Medical
RMTI
$32.9M
| $2.53M | 1.67% |
4,048
+225
| +6% | +$103K |
|
17
Pfizer
PFE
$159B
| $2.52M | 1.66% |
62,659
-7,995
| -11% | -$320K |
|
18
ANI Pharmaceuticals
ANIP
$1.67B
| $2.3M | 1.51% |
32,550
-150
| -0.5% | -$8.82K |
|
19
Digital Turbine
APPS
$1.34B
| $2.29M | 1.51% |
654,895
-34,380
| -5% | -$94.4K |
|
20
CryoPort
CYRX
$815M
| $2.24M | 1.48% |
173,650
+25,750
| +17% | +$280K |
|
21
Microsoft
MSFT
$3.81T
| $2.09M | 1.38% |
17,710
-3,100
| -15% | -$338K |
|
22
LeMaitre Vascular
LMAT
$1.84B
| $1.89M | 1.24% |
60,900
-3,500
| -5% | -$93.4K |
|
23
AtriCure
ATRC
$2.47B
| $1.76M | 1.16% |
65,750
-10,000
| -13% | -$304K |
|
24
Tactile Systems Technology
TCMD
$525M
| $1.73M | 1.14% |
32,774
-1,531
| -4% | -$98.9K |
|
25
Champions Oncology
CSBR
$68.5M
| $1.71M | 1.13% |
174,700
| – | – |
|
Similar funds
AA
WA
AC
BCVI
SWM
HAP
RHIG
CWM
Perkins Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Perkins Capital Management held 141 positions worth $152M, up 18% from $129M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Perkins Capital Management withdrew a net $5.55M in Q1 2019, closing 17 positions and reducing 63 holdings. Its most notable exit was Intel, an estimated $976K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 66% a quarter earlier, followed by Technology and Industrials.
Against the trend, Perkins Capital Management opened a new position in Veritone worth $1.27M.
- Perkins Capital Management's largest Q1 2019 buy was Veritone: 245,000 shares worth $1.27M.
- Perkins Capital Management added most to Pareteum Corporation in Q1 2019, an estimated $1.26M increase.
- Perkins Capital Management's biggest Q1 2019 reduction was Abbott, cutting an estimated $2.81M.
- Perkins Capital Management fully exited Intel in Q1 2019, selling an estimated $976K.
- Perkins Capital Management's ten largest holdings make up 34% of its $152M portfolio in Q1 2019.
- Perkins Capital Management opened 14 new positions and closed 17 in Q1 2019.
- Perkins Capital Management's portfolio value rose 18% quarter-over-quarter to $152M.
Based on Perkins Capital Management's 13F filing for Q1 2019, filed 22 Apr 2019.